Have you been diagnosed with idiopathic pulmonary fibrosis (IPF) but are not currently taking medication to treat the disease? You’re not alone.
Recent insights taken from the Pulmonary Fibrosis Foundation‘s PFF Registry and published in a study corroborates the findings in a separate Pulmonary Fibrosis News survey, revealing that nearly one-third of all IPF patients do not take Esbriet (pirfenidone) or Ofev (nintedanib) — the only two therapies approved by the U.S. Food and Drug Administration to treat the disease. There are a wide range of possible reasons why IPF patients either choose not to take disease-modifying therapies like these or have not been yet prescribed them by their doctors. Pulmonary Fibrosis News hopes to learn what drives these decisions so that we can do a better job of meeting the informational needs of our readers who are still managing IPF without medications.
Our newest survey seeks to better understand the contributing factors that lead to IPF patients not taking Ofev or Esbriet. Please take a few minutes to respond to our survey. As always, we look forward to serving the IPF patient population and offering new perspectives and information on how patients are living life to their fullest in spite of the disease.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?